Similarly, taselisib, assessed as monotherapy in the phase I clinical trial NCT01296555 in patients with PIK3CA-mutant cancers [60], showed a limited benefit in TNBC cohort (n = 17; 10.2%), with a median PFS of 3.0 months (95% CI: 1.6–4.2). Here, PIK3CA is linked to cancer.